ORIC provides Enoxertinib clinical program update
ORIC Pharmaceuticals updated stakeholders on its enozertinib clinical development program on Oct 23, 2026, according to an 8-K filing.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed